Pharmaceutical

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.

Aug 14, 2023 - 20:00
Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline
Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.
Read the original article

Tags:

Previous Article

Valneva pushes FDA approval date for chikungunya vaccine

Next Article

How the pharma industry can benefit from using modular real-time technology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In counties with more Black doctors, Black people live longer, ‘astonishing’ study finds

In counties with more Black doctors, Black people live ...

Apr 15, 2023

Some hoped a new oral vaccine would solve all the polio campaign’s problems. Reality is settling in

Some hoped a new oral vaccine would solve all the polio...

May 27, 2023

Sirolimus by OrphAI Therapeutics for Pulmonary Arterial...

Dec 6, 2023